Company Profile

BIOCON LTD.

NSE : BIOCONBSE : 532523ISIN CODE : INE376G01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE399.90-1.75 (-0.44 % )
PREV CLOSE (Rs.) 401.65
OPEN PRICE (Rs.) 405.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 120491
TODAY'S LOW / HIGH (Rs.)397.80 406.20
52 WK LOW / HIGH (Rs.)211.3 410.35
NSE400.20 -1.65 (-0.41 % )
PREV CLOSE(Rs.) 401.85
OPEN PRICE (Rs.) 403.80
BID PRICE (QTY) 400.20 (1944 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 3194010
TODAY'S LOW / HIGH(Rs.) 397.50 406.35
52 WK LOW / HIGH (Rs.)211.05 410.45

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.00
TTM EPS (Rs.) 3.67
P/E Ratio 109.26
Book Value (Rs.) 62.11
Face Value (Rs.) 5
MCap (Rs. in Mn) 481740.00
Price/Earning (TTM) 89.39
Price/Sales (TTM) 22.06
Price/Book (MRQ) 6.46
PAT Margin (%) 20.19
ROCE (%) 7.62
Incorporation Year : 1978

Management Info :

Kiran Muzumdar Shaw - Chairman Siddharth Mittal - Managing Director

Registered Office :

Address : 20th Km,Hosur Road,Electronic City,
Bengaluru,
Karnataka-560100

Phone : 080 2808 2808

Website : www.biocon.com

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
03Jul07-03-2020$Biocon to invest Rs 1,500 crore on capital expenditure in FY21 Biocon to invest Rs 1,500 cr

Biocon is expecting to invest $200 million (around Rs 1,500 crore) on capital expenditure (capex) in the current fiscal year (FY21), split equally between small molecules and the biosimilars businesses. The capex will be funded through a combination of contribution from internal accruals, debt raise as well as additional private equity investment in Biocon Biologics.

The company's capital expenditure stood at Rs 974.2 crore during 2019-20. Last fiscal, the company invested in a new manufacturing facility in Visakhapatnam for immunosuppressant products, which comes under the small molecules segment.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon is expecting to invest $200 million (around Rs 1,500 cro..
22Jun06-22-2020$Biocon’s arm, DKSH collaborate to commercialize seven generic formulations in South East Asia markets Biocon’s arm, DKSH collabo

Biocon’s subsidiary--Biocon Pharma and DKSH Business Unit Healthcare, have signed an agreement under which DKSH will sell and distribute seven of Biocon Pharma’s generic formulations in Singapore and Thailand. This development is in line with Biocon’s strategy for expansion of its generic formulations business through licensing of its drug products in multiple markets. Thailand and Singapore are the two large markets in the South East Asia region.

Under the terms of the agreement, DKSH will gain an exclusive license to register and commercialize these seven generic formulations from various therapeutic areas like diabetology, cardiology, oncology and immunology, which will be sold under Biocon’s brand in Singapore and Thailand. DKSH will manage marketing and sales as well as logistics for Biocon Pharma, helping drive sales growth through its capabilities and strengths in the medical and pharmacy channels.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovationdriven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


Biocon’s subsidiary--Biocon Pharma and DKSH Business Unit Hea..
22Jun06-22-2020$Biocon informs about press release Biocon informs about press r

Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, Biocon has informed that it has enclosed the press release as on 22nd June 2020 titled ‘Pharma and DKSH Collaborate to commercialize seven generic formulations in South East Asia markets’. The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 of the SEBI (Listing Obligation and D..
22Jun06-22-2020$Biocon surges as its arm collaborates with DKSH Biocon surges as its arm col
Biocon is currently trading at Rs. 387.50, up by 6.00 points or 1.57% from its previous closing of Rs. 381.50 on the BSE.

The scrip opened at Rs. 382.00 and has touched a high and low of Rs. 389.10 and Rs. 382.00 respectively. So far 153776 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 404.50 on 18-Jun-2020 and a 52 week low of Rs. 211.30 on 20-Aug-2019.

Last one week high and low of the scrip stood at Rs. 404.50 and Rs. 378.10 respectively. The current market cap of the company is Rs. 46122.00 crore.

The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 22.30% and 17.03% respectively.

Biocon’s subsidiary--Biocon Pharma and DKSH Business Unit Healthcare, have signed an agreement under which DKSH will sell and distribute seven of Biocon Pharma’s generic formulations in Singapore and Thailand. This development is in line with Biocon’s strategy for expansion of its generic formulations business through licensing of its drug products in multiple markets. Thailand and Singapore are the two large markets in the South East Asia region.

Under the terms of the agreement, DKSH will gain an exclusive license to register and commercialize these seven generic formulations from various therapeutic areas like diabetology, cardiology, oncology and immunology, which will be sold under Biocon’s brand in Singapore and Thailand. DKSH will manage marketing and sales as well as logistics for Biocon Pharma, helping drive sales growth through its capabilities and strengths in the medical and pharmacy channels.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovationdriven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
Biocon is currently trading at Rs. 387.50, up by 6.00 points or..
12Jun06-12-2020$Biocon, Mylan get USFDA’s approval for insulin glargine injection ‘Semglee’ Biocon, Mylan get USFDA’s

Biocon and Mylan N.V. have received an approval from the US Food and Drug Administration (USFDA) for the New Drug Application (NDA) for Semglee (insulin glargine injection), in vial and prefilled pen presentations, to control high blood sugar in adults with type 2 diabetes and adult and pediatric patients with type 1 diabetes. Semglee has an identical amino acid sequence to Sanofi’s Lantus and is approved for the same indications.

Semglee, codeveloped by Mylan and Biocon Biologics, was approved as a drug product under the 505(b)(2) NDA pathway and is now deemed a biologic under section 351(a) in accordance with the Biologics Price Competition and Innovation Act in line with other insulin products.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovationdriven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon and Mylan N.V. have received an approval from the US Foo..
Financials More
Rs. in Millions
QTR Mar 20 ANNUAL 20
Net Profit10224409
Gross Profit 1085 5482
Operating Profit 11064877
Net Sales 482419884
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 15774.00 (0.27%)
M.Cap ( in Cr)
33518.65
Jenburkt Pharma (BSE)
 396.00 (7.64%)
M.Cap ( in Cr)
181.74
Alembic Pharma (BSE)
 915.00 (3.15%)
M.Cap ( in Cr)
17273.71
Divis Lab (BSE)
 2183.00 (1.00%)
M.Cap ( in Cr)
57951.79
Themis Medicare (BSE)
 354.75 (4.34%)
M.Cap ( in Cr)
325.94
Shareholding Pattern More
PROMOTERS 60.67 %
MUTUAL FUNDS/UTI 5.13 %
NON-INSTITUTION 17.03 %
FI/BANKS/INSURANCE 1.62 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes